NasdaqCM - Delayed Quote • USD
Tenax Therapeutics, Inc. (TENX)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 7:15 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -2.4 | -1.64 | -7.42 | -3.63 |
| Low Estimate | -3.06 | -2.2 | -8.14 | -5.32 |
| High Estimate | -1.74 | -1.09 | -6.71 | -1.94 |
| Year Ago EPS | -12 | -4 | -31.04 | -7.42 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -29.6 | -8 | -7.2 | -8.14 |
| EPS Actual | -12 | -4 | -6.4 | -12.98 |
| Difference | 17.6 | 4 | 0.8 | -4.84 |
| Surprise % | 59.50% | 50.00% | 11.10% | -59.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -2.4 | -1.64 | -7.42 | -3.63 |
| 7 Days Ago | -2.4 | -1.64 | -7.42 | -3.63 |
| 30 Days Ago | -1.86 | -1.26 | -6.33 | -3.28 |
| 60 Days Ago | -1.86 | -1.26 | -6.33 | -3.28 |
| 90 Days Ago | -7.2 | -8 | -30 | -27.7 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | TENX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 80.00% | -- | -- | 0.80% |
| Next Qtr. | 59.00% | -- | -- | 9.60% |
| Current Year | 76.10% | -- | -- | 4.50% |
| Next Year | 51.10% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Roth MKM: Buy to Buy | 2/20/2024 |
Related Tickers
REVB Revelation Biosciences, Inc.
2.2400
+4.19%
ENSC Ensysce Biosciences, Inc.
0.5802
-7.66%
AKTX Akari Therapeutics, Plc
1.2100
+1.68%
PHIO Phio Pharmaceuticals Corp.
0.6378
-0.58%
RNAZ TransCode Therapeutics, Inc.
0.5020
-4.64%
ADTX Aditxt, Inc.
2.4100
+2.55%
BPTH Bio-Path Holdings, Inc.
4.2000
+30.03%
HOTH Hoth Therapeutics, Inc.
1.1800
-4.07%
VRAX Virax Biolabs Group Limited
0.6797
+0.18%
NRBO NeuroBo Pharmaceuticals, Inc.
3.4400
-0.58%